Introducing Xandr Monetize
5.9.2019 16:00:00 EEST | Business Wire | Press release
Xandr, AT&T’s advanced advertising & analytics company, today announced the launch of Xandr Monetize, a reimagined strategic selling platform built on the powerful foundation of AppNexus technology. Xandr Monetize will enable media companies to unlock the full value of their premium content and improve the advertising experience for consumers.
As content consumption and viewer attention increasingly fragment, Xandr Monetize gives publishers and media owners full control to navigate the consumer journey and client relationships. The platform offers content owners improved monetization, through better inventory management capabilities, data-driven yield optimization, and differentiated buyer demand. With these powerful tools, Xandr Monetize expands the ways in which publishers can package, sell, and measure the performance of their inventory across all screens and devices.
“Xandr is a trusted partner to media companies, attuned to their challenges and innovating in support of their growth. Now, with the size, scale, and resources of AT&T, we are uniquely positioned to offer the scaled, streamlined selling platform the industry needs,” said Ryan Christensen, SVP of Product, Xandr. “With the launch of Xandr Monetize, our future is primed for collaboration that expands and enriches what media companies offer their advertisers and consumers.”
Monetize Together
Xandr Monetize encompasses all the features of the former AppNexus seller products, including an ad server, supply-side platform (SSP), and yield analytics, and now lays the infrastructure for powerful TV capabilities. The platform unifies and simplifies operations across all inventory and transaction types, as well as demand channels. This allows publishers and media owners to focus on creating more content, innovating with advertising formats, and attracting interested consumers.
“The reality for premium publishers in today’s market is that the major platforms are self-interested, yet Xandr’s goals have been consistently aligned with publishers on the open internet. By collaborating closely with us to differentiate our business and innovating to offer buying the way that advertisers want it, Xandr has enabled us to thrive outside of closed ecosystems. Through premium deals and holistic demand channel management, Xandr Monetize sets us up to strategically optimize global revenue,” said Carsten Schwecke, Chairman of the Board, Media Impact, the joint marketing organization of Axel Springer and Funke Mediengruppe.
Xandr Monetize rounds out Xandr’s platform offering of strategic buying and selling solutions. The direct path between Xandr Invest, the strategic buying platform, and Xandr Monetize facilitates scaled buying and unique demand from AT&T, maximizing working media dollars for buyers and direct sellers alike. Xandr Monetize also allows media companies to sell their inventory through Community, Xandr’s curated premium advertising marketplace, to achieve better yield on their premium multiplatform inventory. Buying access to Community is available solely through Xandr Invest.
Monetize for the Future
While building for the future of monetization, Xandr is already tackling the challenges that digital video buyers and sellers face today. The introduction of Programmatic OTT with Prebid brings programmatic demand to TV by enabling competitive separation across multiple SSPs, on Connected TV devices and other digital TV inventory. Xandr’s Programmatic OTT with Prebid offers greater control on par with TV norms, including brand safety and frequency capping, while supporting simultaneous competition for inventory by all programmatic demand. It is available through real-time bidding and deals.
“Developed with our sales needs in mind, Programmatic OTT with Prebid will be essential to better managing inventory within client campaigns and realizing higher yield for our premium content. We have already tested it and are very excited to deploy this capability across the WarnerMedia digital portfolio,” said Amit Chaturvedi, EVP, Head of Revenue Operations & Ad Products, WarnerMedia Ad Sales.
The launch of Xandr Monetize also introduces Prebid Server Premium, Xandr’s simplified server-side header bidding solution, for both SSP and ad server customers. As server-side header bidding opens new channels of header bidding demand and improves site performance, Prebid Server Premium simplifies setup and increases operational efficiency through reporting insights across formats and a single source of clearing across SSPs.
Xandr Monetize offers holistic inventory and demand channel management so media companies can capitalize on the convergence of direct-sold and programmatic campaigns and maximize the value of their inventory. In addition to robust deal capabilities, Xandr now offers Programmatic Guaranteed, allowing publishers to pre-agree with, and execute on, reserved delivery commitments with programmatic buyers without compromising control over how their inventory is monetized.
Foundational to Xandr Monetize are industry-leading forecasting analytics and data-driven yield optimization. Yield analytics, formerly Yieldex, brings a long history of forecasting insights development with unparalleled accuracy. This allows for planning, pacing, and decisioning for direct and programmatic selling throughout the Xandr Monetize product suite, including current and future TV solutions and the ad server.
“Microsoft relies on Xandr as a programmatic advertising partner that can operate at the massive global scale MSN, Outlook, Xbox, and our Windows App Developers require. Over the last ten years of working together, Xandr has been a thoughtful and flexible partner that has helped Microsoft be successful in our rapidly-changing marketplace and with our unique platform needs. The innovation we’ve seen in Xandr Monetize has augmented our programmatic revenue, while simplifying our ad stack. We look forward to continuing our strategic collaboration and pushing the envelope with the future of advertising,” said Kya Sainsbury-Carter, GM of Global Partner Services, Microsoft.
About Xandr
Xandr is AT&T’s advertising company and a leader in addressable TV, creating a better solution for advertisers and media companies. Xandr Invest and Xandr Monetize, our strategic platforms built on more than a decade of AppNexus’ innovation, optimize media spend across screens for buyers and sellers alike. Community, powered by Xandr, is a curated marketplace of premium publishers, providing access to unique consumer insights in a brand-safe environment. For more than 143 years, AT&T has used data and technology to inform and improve the consumer experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005274/en/
Contact information
Xandr Press Contact
Caroline Smith
914.446.3006
caroline.smith@xandr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress 2026 on July 2 in Munich, Germany. BOT+BAL demonstrated clinically meaningful long-term survival in a heavily pretreated patient population with historically limited benefit from conventional immune checkpoint inhibitors and few durable treatment options after progression on standard therapies. With extended follow-up, median overall survival was 21.2 months and the three-year overall survival rate was 33%, with the Kaplan-Meier curve showing a plateau beyond two years
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 12:12:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to-end AI and cyber exposure assessment engine with a structured execution model that spans from assessment to remediation. At the cor
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 11:00:00 EEST | Press release
Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countries published in “The Allianz 3am Report 2026.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260703907741/en/ Allianz / IPSOS “What Worries the World” Study, April – June 2026. Financial worries, which include concerns about “rising cost of living” (71%) and “insufficient income” (51%), increased in seven out of eight countries surveyed year over year, moving up in the ranking of top three worries in Brazil, France, Germany, and the U.K., while remaining stable in Italy. The strongest increases are observed in Australia and Indonesia, where financial concerns have remained the leading worry, as well
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 09:40:00 EEST | Press release
Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in Tokyo on July 6, 2026. Fusion energy has the potential to shift the foundation of energy from natural resources to advanced technology by reproducing, on Earth, the sam
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 08:15:00 EEST | Press release
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discovery and development of a novel class of payloads for antibody-drug conjugates. The company's platform is built around next-generation N-myristoyltransferase inhibitor (NMTi) payloads, a differentiated mechanism of action designed to address the narrow therapeutic windows and tolerability challenges that have limited earlier generations of ADCs, such as TOPO-1 and tubulin inhibitor payload classes. Myricx Bio's two lead ADC assets, directed towards the established targets B7-H3 and HER2, are designed to bring this differentiated approach to patients across a broad ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom